• Data presented at ASCO Annual Meeting
• CEP-1 Study: NOX66 in combination with low-dose carboplatin in late-stage cancer
• Ability to halt cancer progress with lower incidence of chemotherapy-associated side-effects.
Sydney, 5 June 2018: Noxopharm (ASX:NOX) today presented key end-of-study clinical data from its Phase 1b CEP-1 clinical study to the 2018 Annual Meeting of American Society of Clinical Oncology in Chicago, USA.
The ultimate objective of the Chemotherapy Enhancement Program (CEP) is to demonstrate that NOX66 can improve both the anti-cancer benefit and the safety of commonly used cytotoxic chemotherapy drugs.
For further information please download PDF attached:
Download this document